Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients

Eckstein M, Lieb V, Jung R, Sikic D, Weigelt K, Stöhr R, Geppert CI, Weyerer V, Bertz S, Serrero G, Yue B, Hartmann A, Wullich B, Taubert H, Wach S (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Cells MDPI

Book Volume: 10

Journal Issue: 7

DOI: 10.3390/cells10071796

Abstract

Urothelial bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide and accounts for approximately 3% of global cancer diagnoses. We are interested in prognostic markers that may characterize tumor cells (TCs) and immune cells (ICs) and their relationship in BCa. A potential candidate marker that meets these criteria is progranulin (GP88), which is expressed separately in TCs and ICs. We analyzed GP88 expression by immunohistochemistry (IHC) in 196 muscle-invasive BCa samples using a tissue microarray. The immunoreactive score for GP88 staining in TCs and the percentage of GP88-positive ICs was determined. An easy cutoff for the staining status of TCs (positive vs. negative) and ICs (0% vs. >0%) and, more generally, negative vs. positive GP88 staining could be applied. We detected 93 patients (47.4%) and 92 patients (46.9%) with GP88-positive TCs or ICs, respectively. The IHC results were correlated with clinicopathological and survival data. Positive GP88 staining in TCs appeared to be an independent poor prognostic factor for disease-specific survival (DSS) (RR (relative risk) = 1.74; p = 0.009) and recurrence-free survival (RFS) (RR = 1.92; p = 0.002). In contrast, negative GP88 staining in ICs was an independent negative predictor for overall survival (OS) (RR = 2.18; p < 0.001), DSS (RR = 2.84; p < 0.001) and RFS (RR = 2.91; p < 0.001) in multivariate Cox's regression analysis. When combining GP88 staining in TCs and ICs, a specific combination of GP88-positive TCs and GP88-negative ICs was associated with a 2.54-fold increased risk of death, a 4.21-fold increased risk of disease-specific death and a 4.81-fold increased risk of recurrence compared to GP88-negative TCs and GP88-positive ICs. In summary, GP88 positivity in TCs is a negative prognostic factor for DSS and RFS. In addition, GP88 positivity can mark ICs that are associated with a good prognosis (OS, DSS and RFS). The combination of GP88 staining in TCs and ICs appears to be a significant independent prognostic biomarker in muscle-invasive BCa.

Authors with CRIS profile

Markus Eckstein Institute of Pathology Verena Lieb Urologische Klinik Danijel Sikic Medizinische Fakultät Carol-Immanuel Geppert Institute of Pathology Veronika Bahlinger Institute of Pathology Simone Bertz Institute of Pathology Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Bernd Wullich Lehrstuhl für Urologie Helge Taubert Professur für Molekulare Urologie Sven Wach Medizinische Fakultät

Involved external institutions

A&G Pharmaceutical US United States (USA) (US)

How to cite

APA:

Eckstein, M., Lieb, V., Jung, R., Sikic, D., Weigelt, K., Stöhr, R.,... Wach, S. (2021). Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients. Cells, 10(7). https://dx.doi.org/10.3390/cells10071796

MLA:

Eckstein, Markus, et al. "Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients." Cells 10.7 (2021).

BibTeX: Download